Crossmark

Liver Metastases are Associated with a Short Post-Progression Survival in a Real-World Group of Patients with Melanoma Treated with Checkpoint Inhibitors

Crossref DOI link: https://doi.org/10.1007/s40487-024-00320-4

Published Online: 2024-12-11

Published Print: 2025-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Mengoni, Miriam

Tüting, Thomas

Gaffal, Evelyn

Braun, Andreas D. https://orcid.org/0000-0002-6954-0633
Funding

Funding for this research was provided by:

Arbeitsgemeinschaft Dermatologische Forschung
License Information

Text and Data Mining valid from 2024-12-11

Version of Record valid from 2024-12-11
More Information

Article History

Received: 3 October 2024

Accepted: 20 November 2024

First Online: 11 December 2024

Declarations

:

: Unrelated to this work, Miriam Mengoni reports travel support from Pierre Fabre Pharma GmbH and Sun Pharmaceutical Industries Ltd and honoraria for presentations and advisory tasks from Novartis Pharma GmbH, Sun Pharmaceutical Industries Ltd., Kyowa Kirin GmbH, Stemline Therapeutics B.V. and MSD Sharp & Dohme GmbH. Andreas Dominik Braun reports honoraria for advisory tasks from MSD Sharp & Dohme GmbH unrelated to this work. Thomas Tüting and Evelyn Gaffal have no conflicts of interest to declare.

: This retrospective study was approved by the institutional ethics committee of the Otto-von-Guericke University Magdeburg (Approval number 145/21, Ethics Committee, Otto-von-Guericke University Magdeburg, Germany). Patients still alive have provided written consent for this study. For deceased patients, as well as those unable to provide written consent, local regulations from Saxony-Anhalt, Germany waive the need for patient consent for retrospective analysis of anonymized treatment data (§17 KHG LSA).

Document is current

Any future updates will be listed below